PortalPublikationenA phase I study of Danusertib (PHA-739358) in adult patients...

A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

Standard

A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. / Borthakur, Gautam; Dombret, Herve; Schafhausen, Philippe; Brummendorf, Tim Henrik; Boissel, Nicolas; Jabbour, Elias; Mariani, Mariangela; Capolongo, Laura; Carpinelli, Patrizia; Davite, Cristina; Kantarjian, Hagop; Cortes, Jorge E.

in: HAEMATOLOGICA, 17.04.2015.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Borthakur, G, Dombret, H, Schafhausen, P, Brummendorf, TH, Boissel, N, Jabbour, E, Mariani, M, Capolongo, L, Carpinelli, P, Davite, C, Kantarjian, H & Cortes, JE 2015, 'A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy', HAEMATOLOGICA. https://doi.org/10.3324/haematol.2014.115279

APA

Borthakur, G., Dombret, H., Schafhausen, P., Brummendorf, T. H., Boissel, N., Jabbour, E., Mariani, M., Capolongo, L., Carpinelli, P., Davite, C., Kantarjian, H., & Cortes, J. E. (2015). A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. HAEMATOLOGICA. https://doi.org/10.3324/haematol.2014.115279

Vancouver

Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E et al. A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. HAEMATOLOGICA. 2015 Apr 17. https://doi.org/10.3324/haematol.2014.115279

Bibtex

@article{371d07622271464a9a7d47e573325d15,
title = "A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy",
abstract = "Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study was conducted in patients with accelerated or blastic phase chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. Two dosing schedules were studied: Schedule A: danusertib by 3-hour IV infusion daily for 7 consecutive days (Days 1-7) in a 14-day cycle and Schedule B: danusertib by 3-hour IV infusion daily for 14 consecutive days (Days 1-14) in a 21-day cycle. A total of 37 patients were treated, 29 treated by Schedule A and 8 by Schedule B. The recommended Phase II dose for Schedule A was 180 mg/m2. Enrollment to Schedule B was stopped early because of logistical problems in the frequency of infusions. Febrile neutropenia and mucositis were dose-limiting toxicities in Schedule A. Four patients with T315I ABL kinase mutation, all in Schedule A, responded. Danusertib has an acceptable toxicity profile and is active in patients with Bcr-Abl-associated advanced hematologic malignancies. The study was registered with the European Clinical Trails Data Base (EudraCT Number 2007-004070-18).",
author = "Gautam Borthakur and Herve Dombret and Philippe Schafhausen and Brummendorf, {Tim Henrik} and Nicolas Boissel and Elias Jabbour and Mariangela Mariani and Laura Capolongo and Patrizia Carpinelli and Cristina Davite and Hagop Kantarjian and Cortes, {Jorge E}",
note = "Copyright {\textcopyright} 2015, Ferrata Storti Foundation.",
year = "2015",
month = apr,
day = "17",
doi = "10.3324/haematol.2014.115279",
language = "English",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",

}

RIS

TY - JOUR

T1 - A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

AU - Borthakur, Gautam

AU - Dombret, Herve

AU - Schafhausen, Philippe

AU - Brummendorf, Tim Henrik

AU - Boissel, Nicolas

AU - Jabbour, Elias

AU - Mariani, Mariangela

AU - Capolongo, Laura

AU - Carpinelli, Patrizia

AU - Davite, Cristina

AU - Kantarjian, Hagop

AU - Cortes, Jorge E

N1 - Copyright © 2015, Ferrata Storti Foundation.

PY - 2015/4/17

Y1 - 2015/4/17

N2 - Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study was conducted in patients with accelerated or blastic phase chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. Two dosing schedules were studied: Schedule A: danusertib by 3-hour IV infusion daily for 7 consecutive days (Days 1-7) in a 14-day cycle and Schedule B: danusertib by 3-hour IV infusion daily for 14 consecutive days (Days 1-14) in a 21-day cycle. A total of 37 patients were treated, 29 treated by Schedule A and 8 by Schedule B. The recommended Phase II dose for Schedule A was 180 mg/m2. Enrollment to Schedule B was stopped early because of logistical problems in the frequency of infusions. Febrile neutropenia and mucositis were dose-limiting toxicities in Schedule A. Four patients with T315I ABL kinase mutation, all in Schedule A, responded. Danusertib has an acceptable toxicity profile and is active in patients with Bcr-Abl-associated advanced hematologic malignancies. The study was registered with the European Clinical Trails Data Base (EudraCT Number 2007-004070-18).

AB - Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study was conducted in patients with accelerated or blastic phase chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. Two dosing schedules were studied: Schedule A: danusertib by 3-hour IV infusion daily for 7 consecutive days (Days 1-7) in a 14-day cycle and Schedule B: danusertib by 3-hour IV infusion daily for 14 consecutive days (Days 1-14) in a 21-day cycle. A total of 37 patients were treated, 29 treated by Schedule A and 8 by Schedule B. The recommended Phase II dose for Schedule A was 180 mg/m2. Enrollment to Schedule B was stopped early because of logistical problems in the frequency of infusions. Febrile neutropenia and mucositis were dose-limiting toxicities in Schedule A. Four patients with T315I ABL kinase mutation, all in Schedule A, responded. Danusertib has an acceptable toxicity profile and is active in patients with Bcr-Abl-associated advanced hematologic malignancies. The study was registered with the European Clinical Trails Data Base (EudraCT Number 2007-004070-18).

U2 - 10.3324/haematol.2014.115279

DO - 10.3324/haematol.2014.115279

M3 - SCORING: Journal article

C2 - 25887498

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

ER -